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1. Introduction 
1.1. Defining anxiety and fear 
Anxiety is a term often used to encompass feelings of apprehension, dread, unease or 
similarly unpleasant emotions. Trait anxiety defines the affect of an organism over time and 
across situations, whereas state anxiety is the response or adaptation to a given situation [1].  
Anxiety can be differentiated from fear, both biologically and behaviorally [see 1 for an 
extensive review]. Converging theories and evidence from clinical psychology and 
comparative neuroscience suggest that fear can be considered a negatively-valenced 
emotion that is brief, focused on the present, occurs in situations of specific threat, and aids 
in avoidance or escape [1,2]. Anxiety, on the other hand, is a negatively-valenced emotion 
that is characterized by sustained hyperarousal in response to uncertainty, is thus future-
focused, and aids in defensive approach or risk assessment [1,2]. Both anxiety and fear are 
emotions experienced by all individuals and can serve to be adaptive in shaping decisions 
and behaviors related to survival of an organism [1,3]. However, when excessive, or 
pathological, or triggered inappropriately, fear and anxiety form the basis of a variety of 
anxiety disorders [3,4,5; Table 1]. As illustrated by Table 1, some anxiety disorders such as 
generalized anxiety disorder (GAD) or obsessive-compulsive disorder (OCD) are 
characterized by excessive anxiety as defined above [1]. However, other anxiety disorders 
are characterized, at least in part, by excessive and inappropriate fear, such as posttraumatic 
stress disorder (PTSD), specific phobias and social anxiety disorder [1,3; Table 1]. Thus, it is 
important to understand the neurobiology of both anxiety and fear to obtain a 
comprehensive picture of the physiological basis of anxiety disorders. 
1.2. Anxiety disorders 
One in three people will develop one of the anxiety disorders outlined by Table 1 within 
their life-time, with the life-time prevalence at least two times more likely for women [5,6]. 
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Furthermore, individuals may present with one or more comorbid anxiety disorders, and 
anxiety disorders are highly likely to be comorbid with other psychiatric illnesses, such as 
major depressive disorder, psychosis, mania, and substance abuse disorder [4-6]. Several 
non-psychiatric disorders are also associated with anxiety disorders, and these include 
hyperthyroidism, Cushing’s disease and mitral value prolapse [4,5]. Thus, anxiety disorders 
are one of the most prevalent psychiatric disorders, posing great personal, economic, and 
societal burdens [4-6].   
 
Generalized Anxiety Disorder (GAD) 
Excessive worry occurring more days than not over at least a 6 month period, accompanied 
by restlessness, fatigue, sleep disturbances, muscle tension or irritability.   
Posttraumatic Stress Disorder (PTSD) 
Characterized by a history of trauma and symptoms related to avoidance, re-experiencing, 
and physiological hyperarousal in the face of triggering cue. 
Obsessive-Compulsive Disorder (OCD) 
Compulsions (repeated actions) produced to reduce anxiety associated with obsessions 
(unwanted, intrusive thoughts). 
Panic Disorder 
Characterized by panic attacks; a period of intense fear or discomfort accompanied by a 
variety of physiological symptoms (e.g. sweating, trembling, chest pains, tachycardia). 
Agoraphobia 
Fear and avoidance of situations from which escape would be difficult in the event of 
having panic-like symptoms. 
Specific Phobia 
Excessive or unreasonable fear in anticipation or in response to a specific object or 
situation.   
Social Anxiety Disorder (Social Phobia) 
Excessive/unreasonable fear and avoidance of social situations (including performances) in 
which the person is exposed to unfamiliar people or possible scrutiny by others.   
Table 1. Major Classes of Anxiety Disorders [4,5,7] 
1.3. Goals of the current review 
The neurobiological bases of anxiety and fear appear to be very similar across species [1], 
thus complementary findings from both animal models (most often rodents) and human 
studies can contribute to theories of the neurobiological basis of anxiety disorders. State fear 
within animal models is most often studied by measures of freezing and fear-potentiated 
startle, both acquired via classical conditioning of rodents [1,8]. State anxiety, on the other 
hand, is most often studied using apparatus such as an open field, elevated plus maze, or 
light-dark box, which all take advantage of the rodent’s preference for familiar, dark, and/or 
enclosed areas [1,9]. Notably, these paradigms do not rely on the processes underlying 
classical conditioning, although McNaughton and Corr [2] caution against defining fear 
verses anxiety as conditioned versus unconditioned responses. While trait fear is not well-
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defined by animal studies [1], trait anxiety is often examined in animal models by the use of 
selective breeding, resulting in high- and low-anxiety strains and lines of rodents [for 
example, see 1, 10]. However, one can argue that experimental manipulations (such as early-
life stress or amphetamine withdrawal) that drive a group of animals towards greater fear- 
and anxiety-like phenotypes also examine the underlying basis of trait fear or anxiety [e.g. 
11, 12]. As noted by Sylver et al [1] clinical studies most often examine trait anxiety, whereas 
experiments involving animal models most often focus on state anxiety and fear, and then 
relate these findings to concepts associated with trait anxiety. Regardless, both human and 
animal studies suggest an important role for the amygdala, and subregions within, in 
mediating fear and anxiety, and in the manifestation of anxiety disorders (Sections 2 and 3). 
Therefore, the goals of this review are to first evaluate and integrate classical and recent 
findings from human studies and relevant animal models that reveal the specific role the 
amygdala plays in fear and anxiety, and then to elucidate how anxiolytic drugs may affect 
the amygdala function to ameliorate heightened fear and/or anxiety. This is important, 
given that traditional drug and cognitive behavioral therapy (CBT) are effective in reducing 
symptoms of the various anxiety disorders for many individuals, but often do not provide 
long-term relief, and relapse is a common post-treatment outcome [as reviewed by 3]. 
Therefore, the final goal of the current review is to identify future potential therapeutic 
targets for the treatment of anxiety disorders. 
2. Human imaging studies: Amygdala hyperfunction and anxiety 
disorders 
2.1. Amygdala reactivity and anxiogenic or fearful stimuli 
Human imaging studies that explore the neurobiological bases of anxiety or fear processing 
typically use functional magnetic resonance imaging (fMRI) or positron emission tomography 
(PET) as measures of neural activity or cerebral blood flow. Imaging experiments that are 
designed to study neural reactivity to fearful stimuli utilize either conditioned fear paradigms 
similar to those used in animal models, or involve the presentation of unconditioned stimuli 
such as fearful faces [1]. It has become clear that masked stimuli can elicit conditioned and 
unconditioned fear responses from human subjects, suggesting unconscious, implicit 
processing of these cues [as reviewed by 1]. Similarly, increased activity of the amygdala is 
observed in response to both conditioned and unconditioned fearful stimuli, independent of 
whether the subject is aware of the stimulus [1,13-16]. 
Comparable studies that have examined neural correlates of anxiety in healthy controls are 
limited. One of the reasons for this is that many studies use fearful stimuli, such as the 
fearful faces or conditioned fear paradigms [1], blurring the distinction between fear and 
anxiety. Therefore, conclusions regarding neural bases of anxiety are better drawn from 
studies that include trait anxiety as a variable while utilizing fearful stimuli, or those fewer 
studies in which an anxiogenic situation is created within the experimental design. Like for 
studies of fear processing, the majority of these studies show a relationship between trait 
anxiety and greater amygdala reactivity [as reviewed by 17]. For example, a study of healthy 
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subjects found that reactivity of the amygdala was positively correlated with anticipatory 
anxiety, and when the anticipated event was imminent, amygdala activation positively 
correlated with the degree of trait anxiety [18]. Furthermore, college students who scored in 
the upper 15th percentile for trait anxiety show greater amygdala reactivity to emotional 
faces as compared to students who scored in the normative range, suggesting that anxiety-
prone individuals have greater amygdala reactivity [19]. A similar hyperactivity of the 
amygdala in high trait anxiety participants is noted when a masked emotional faces or 
unattended faces paradigm are used [20,21], suggesting the individual does not need to be 
aware of the stimulus to exhibit heightened amygdala activity. Interestingly, Etkin et al., [21] 
differentiate between different subregions of the amygdala (see Section 3.1 for more details 
on amygdala subregions), with the basolateral amygdala activated during masked 
presentations of emotional faces while the dorsal/central amygdala was activated during 
unmasked presentations. Thus, there may be subregion specificity within the amygdala 
when processing unconscious versus conscious emotionally-valenced stimuli.    
When gender has been examined as a factor in populations of healthy subjects, higher trait 
anxiety is associated with greater amygdala responses to unattended fearful faces in female 
but not male participants [22]. A further factor potentially mediating the relationship 
between trait anxiety and amygdala reactivity appears to be perceived social support. To 
illustrate, Hyde et al. [17] show a positive correlation between the degree of trait anxiety and 
amygdala reactivity to fearful faces in subjects that report below-average social support, but 
not in those who report above average support. Related, it is also thought that the degree of 
social anxiety rather than trait anxiety may be more closely related to amygdala reactivity to 
emotional faces [23]. These factors, and other similar considerations, may explain why some, 
but not all, studies show a positive correlation between trait anxiety and amygdala 
reactivity in non-patient populations [18-21,23].  
2.2. Amygdala reactivity in anxiety disorders 
Hyperactivity of the amygdala in response to negatively-valenced stimuli also appears to be 
a common finding from a variety of clinical anxiety populations [16]. For example, 
individuals suffering from social anxiety disorder show heightened amygdala responses to 
both social and non-social highly emotive stimuli as compared to healthy control groups, 
with the degree of social anxiety positively correlated with amygdala reactivity  [24-27]. 
Furthermore, activation of the amygdala by non-social stimuli has been correlated with trait 
anxiety in social anxiety disorder, leading to the conclusion that social anxiety disorder is 
characterized by a more general dysfunction in   emotional processing in addition to altered 
processing of social stimuli and situations [26]. Importantly, reduced symptoms in a public 
speaking situation following either CBT or antidepressant treatment was associated with 
reduced amygdala reactivity [24], further suggesting a tight link between symptomology 
and amygdala reactivity in social anxiety disorder.   
Like social anxiety disorder, a commonly replicated finding from various PTSD populations 
is hyperactivity of the amygdala in response to masked fearful faces or trauma-related 
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stimuli [3,28,29]. This manifests as higher amygdala reactivity as compared to non-PTSD 
groups and/or a positive correlation between severity of PTSD symptoms and amygdala 
reactivity [28,30-33]. Furthermore, in a group of unmedicated acute PTSD subjects (1 month 
post trauma), the degree of PTSD symptoms also positively correlated with activity of the 
amygdala in response to masked fearful faces [34]. Thus, amygdala hyperactivity observed 
in chronic PTSD appears early in the disorder. However, it should be noted that in these 
same individuals, the degree of PTSD symptoms negatively correlated with activity in the 
amygdala in response to unmasked fearful faces [34]. This suggests amygdala hypoactivity 
in response to consciously-processed fearful stimuli in the early stages of PTSD, further 
implying a dissociation in amygdala activity in response to consciously-processed versus 
unconsciously-processed fearful stimuli. Interestingly, activity of the amygdala in response 
to fearful stimuli might not only be characteristic of PTSD, but might predict treatment 
outcome. Bryant et al [33] show that individuals diagnosed with PTSD that do not respond 
to CBT (8 one weekly sessions) show significantly greater pre-treatment amygdala 
activation in response to masked fearful faces as compared to those PTSD subjects who did 
respond to CBT, as defined by a 50% or more reduction in scores on the Clinician-
Administered PTSD Scale (CAPS). Therefore, hyper-function of the amygdala might provide 
a useful tool for future selections of treatment options for PTSD. 
Similar to PTSD and social anxiety disorder, amygdala hyperactivity as a result of highly 
emotional stimuli presentation or symptom provocation has been observed in specific 
phobia, panic disorder, and OCD [35-38]. Given the prevalence of GAD, it is surprising that 
few studies have assessed amygdala reactivity in GAD participants. Somewhat more 
surprising is that of those studies that have determined amygdala activity in response to 
emotive stimuli in adult GAD populations, a lack of amygdala hyperactivity has been 
observed [27,39,40]. This stands in contrast to findings from pediatric GAD, where 
hyperactivity of the amygdala is apparent in response to emotional stimuli and positively 
correlated with symptom severity [41,42]. However, recent findings examining amygdala 
function within paradigms that elicit anticipatory anxiety or emotional conflict have 
implicated a role for amygdala hyper-reactivity in adult GAD populations. For example, 
Nitschke et al. [43] report greater anticipatory amygdala activation in response to both 
emotional and neutral images in adult GAD subjects.  Furthermore, Etkin et al [44] found 
that adult participants with GAD exhibited poor performance on a task that involved 
emotional conflict (incongruent visual emotional stimuli), accompanied by a failure of the 
frontal cortex to exert negative top-down control of amygdala activity (see Section  3.1 for 
more on top-down control of the amygdala). Therefore, amygdala hypofunction in adult 
GAD might be better revealed by imaging studies that create anxiogenic or conflict 
situations, rather than the standard presentation of fearful stimuli. While this conclusion 
requires direct testing, the findings that anxiogenic but not fearful stimuli reveal 
hypofunction of the amygdala in GAD, whereas fearful stimuli consistently elicit amygdala 
hyper-reactivity in other anxiety disorders (such as social anxiety disorder, PTSD and also 
pediatric GAD), suggests a neural dichotomy between GAD and other anxiety disorders on 
the anxiety to fear continuum.   
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In summary, there appears to be reasonable overlap across various experimental paradigms 
and study populations to conclude that the amygdala is reactive to fearful stimuli and 
anxiogenic situations, and exhibits hyper-function to emotive stimuli, anxiogenic situations 
and/or symptom provocation in anxiety disorders. However, which neurotransmitters and 
subregions of the amygdala mediate these responses if often better answered by animal 
studies, where spatial and neurochemical resolution is greatly improved over human 
imaging studies. 
3. Amygdala subregions, connectivity, neurotransmission and 
fear/anxiety 
3.1. The role of amygdala subregions in mediating fear and anxiety 
As discussed above, hyper-function of the amygdala appears to be a key component of 
human anxiety disorders. However, the contribution of particular amygdalar subregions in 
the development and maintenance of this hyperactive state in humans is still being 
established. Only very recently have refinements in the acquisition and analysis of fMRI 
data allowed subregion function to be segregated effectively during emotional tasks such as 
avoidance learning [45] and facial expression recognition [21,46]. Similarly, effective 
structural identification of human amygdalar subregions and assessment of their functional 
connectivity using imaging techniques is still fairly new [for example, see 47-51]. Therefore, 
most of our understanding of causal neurochemical pathways in amygdalar circuitry related 
to fear and anxiety has derived from extensive studies using rodent and non-human primate 
models [for example, see 9,52-58]. 
Anatomical arrangement of the mammalian amygdala appears to have been evolutionarily 
conserved, with particular subregions being connected to homologous brain structures 
across species [as reviewed by 59]. The lateral (LA) nucleus of the amygdala is reciprocally 
connected with the auditory, somatosensory and visual sensory association centers in the 
temporal and insular cortices [59], and in rats also receives further auditory information via 
projections from the posterior thalamus [59,60]. The medial amygdala (MeA) is reciprocally 
connected with the accessory olfactory bulb and many hypothalamic and preoptic nuclei 
[59,61], creating a locus for assimilation of olfactory stimuli and information regarding 
internal hormonal state [62,63]. Information summated within the LA and MeA is then 
conveyed to the adjacent basal (B) and accessory basal (AB) nuclei [64], which also receive 
projections from the CA1 and subiculum areas of the ventral hippocampus [65-67]. The 
B/AB nuclei send excitatory and inhibitory projections back to the LA and MeA [64,68], 
creating a localized circuit that may assist in fine-tuning the filtering of sensory input into 
these regions [64]. Excitatory projections from this basolateral (BLA) complex target the 
central nucleus of the amygdala (CeA) either directly or via a series of GABAergic 
interneurons known as intercalated (ITC) cells located between the BLA and CeA [69], 
providing an effective means of gating CeA activity and output through a combination of 
direct excitation and feed-forward inhibition [64,70,71]. The CeA itself, principally the medial 
sector, sends GABAergic projections to brainstem, hypothalamic and basal forebrain regions 
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that control expression of autonomic, hormonal and behavioral responses to emotive 
situations 72,73]. It should also be noted that in addition to activating the CeA, the BLA 
projects to the adjacent bed nucleus of the stria terminalis (BNST), which in turn targets many 
of the same regions as the CeA to produce similar behavioral and physiological responses [73]. 
The MeA is also able to regulate these responses not only via its influence on hypothalamic 
nuclei and brainstem targets, but by modulating activity in the BNST and CeA [61,64].   
The functional connectivity between the BLA, MeA and CeA ensures that sensory and 
contextual information associated with emotional situations, such as fearful or anxiogenic 
circumstances, is channeled to effector regions to produce appropriate responses necessary 
for survival. The BLA and CeA, unlike the MeA, do not appear necessary for expression of 
unconditioned fear responses to olfactory stimuli in rodents, e.g., to novel presentation of 
predator odor [74-76], although the BLA does appear to play a role in responses to other 
types of unconditioned stimuli [77,78]. However, the functional arrangement of the BLA and 
CeA with other regions facilitates learning about the situation, such that appropriate 
reactions are maintained if cues associated with initial exposure are experienced again. The 
BLA in particular appears to play a crucial role in encoding positive or negative salience to 
relevant stimuli for future reference, as indicated by numerous studies showing that the 
BLA is required for fear learning and acquisition of conditioned fear responses [see 56,60]. 
Once fear conditioning is acquired, the CeA is necessary for expression of the conditioned 
response [56,60], the magnitude of which will be influenced by BLA gating of CeA activity 
and output. Similarly, the BLA is needed for acquisition and expression of fear extinction 
[79,80], which requires a subject to learn that expression of a previously conditioned fear 
response is no longer necessary when the conditioned stimulus no longer predicts an 
aversive event [57,81]. To achieve this, the BLA must integrate new sensory information 
(absence of the unconditioned aversive stimulus) that will result in a dampening of CeA 
excitation. This may result from increased BLA excitation of ITC cells during fear extinction 
acquisition to enhance feed-forward inhibition of the CeA [79,82,83], followed by structural 
remodeling within the BLA during consolidation of the extinction memory to inhibit later 
BLA output [79]. However, while the roles of the BLA and CeA in fear behaviors are well 
established, their contribution to anxiety is less clear, especially for the CeA. Animal studies 
suggest that changes in BLA and CeA activity can alter state anxiety [9; also see Section 3.2.]. 
However, most investigations have focused on the BLA with the exact role of the CeA 
remaining ill-defined [for example, see 84,85], although it appears that BLA to CeA circuitry 
can directly regulate anxiety-like behavior as measured on the elevated plus maze [EPM, 
86]. This direct control is thought to result from BLA excitation of GABAergic neurons in the 
lateral CeA to induce feed-forward inhibition of output from the medial CeA [86], similar to 
that induced by BLA excitation of ITC cells during fear extinction. Thus, suppression of CeA 
output may be equally important for mediating expression of both fear and anxiety. 
Alternatively, some studies have suggested that it is BLA activation of the BNST, not of the 
CeA, that is responsible for mediating anxiety-like behavior as measured using light-
potentiated startle responses in rodents [56,87,88]. Startle responses are also potentiated by 
corticotropin releasing factor (CRF) infused into the BNST [56]. This effect is presumed to 
result through facilitation of glutamate release from BLA afferents by CRF neurons that 
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originate in the lateral CeA [88,89], implying that even if BNST is the principal output center 
for certain types of anxiety-like behaviors, the CeA may still play some modulatory role. 
Furthermore, the MeA has been strongly implicated in animal models of state anxiety [for 
example, see 90-93 and see Section 3.2], but whether its effects involve modulation of CeA 
activity is unknown. To direct translational research into the neurological underpinning of 
anxiety disorders more effectively, animal studies employing as wide a range of state 
anxiety paradigms as possible, along with animal models that generate trait anxiety, are 
required to establish the exact nature of CeA involvement and of amygdala subregion 
interplay in mediating anxiety-like behavior.    
It is important to remember that while the amygdala can mediate fear and anxiety-like 
behavior, other brain regions play a major role in expression of these states, presumably by 
influencing activity in particular amygdalar subregions to alter the balance of output from 
the CeA. For example, input from the ventral hippocampus to the B/AB nuclei within the 
BLA is required for expression of conditioned fear responses to contextual cues in rodents 
and humans [60,94,95], and so receipt of this information presumably increases BLA 
activity, to in turn enhance CeA output in the aversive context. In rodents, the ventromedial 
prefrontal cortex (vmPFC) also appears to be crucial in regulating amygdalar activity, 
especially during fearful experiences [79]. The prelimbic (PL) subregion of the vmPFC can 
enhance conditioned fear expression via excitatory projections to the BLA and CeA [96-98].  
In contrast, expression of conditioned fear appears to be decreased by activation of the 
infralimbic (IL) subregion of the vmPFC [99, but see 100]. The IL cortex is also required for 
effective consolidation and recall of fear extinction memories [79,98]. Both decreased 
conditioned fear responding and fear extinction require suppression of CeA output, which 
is thought to result in part via IL cortex stimulation of the series of inhibitory ITC cells that 
project to the CeA [71,79,96,101]. The bidirectional roles of the PL and IL cortices in 
regulating conditioned fear through opposing influences on CeA activity and output imply 
that imbalance in the influence of either cortical structure could contribute to amygdala 
hyperactivity seen in anxiety disorders characterized by excessive and inappropriate fear 
(see Table 1). This is supported by fMRI studies investigating neural correlates of impaired 
fear extinction in PTSD patients, who compared to healthy subjects show hyperactivity of 
the amygdala during extinction learning [102]. This enhanced amygdala function in PTSD 
patients is accompanied by greater activation of the dorsal anterior cingulate cortex (dACC, 
functionally equivalent to the rodent PL cortex, [3,57], which is also present during recall of 
the extinction memory [102]. This is in line with rodent studies demonstrating potentiated 
fear conditioning upon PL cortex activation [98]. However, PTSD individuals exhibit 
hypoactivation of the ventral portion of the vmPFC (equivalent to rodent IL cortex, [3,57]) 
during extinction learning and recall [102,103]. Human imaging studies also suggest that 
impaired regulation of amygdala activity by the ventral vmPFC may contribute to anxiety 
disorders characterized by hypervigilance in the absence of conditioned stimuli, such as in 
GAD. Specifically, the strength of the connection between the vmPFC and the amygdala, as 
measured using diffusion tensor imaging, predicts levels of self-reported trait anxiety, such 
that weaker connections are seen in more anxious individuals [104]. As mentioned earlier 
(Section 2.2), participants with GAD exhibited a failure of the vmPFC to exert negative top-
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down control of amygdala activity during a task that involved emotional conflict [44]. 
Further, resting state fMRI revealed that in anxious individuals, vmPFC activity was 
negatively correlated with amygdala activity, while a positive relationship was observed for 
low anxious subjects [105]. The combination of animal and human studies strongly indicates 
that inadequate suppression by the ventral portion of the vmPFC, most likely of the CeA, is 
a key factor in amygdala hyperactivity underlying the emergence of excessive fear and 
anxiety states.     
3.2. Monoaminergic neurotransmission in the amygdala: Relation to fear and 
anxiety 
The monoamine neurotransmitters (serotonin, dopamine and norepinephrine) have long 
been associated with fear and anxiety, and drugs that alter monoaminergic function are 
often effective across the range of anxiety disorders [8, 9, 52, 55]. Animal studies suggest a 
variety of anxiogenic stressors or fearful stimuli increase monoamine levels in the amygdala. 
To illustrate, increased serotonin (5-HT) release or increased activity of 5-HT neurons in the 
amygdala have been observed in response to restraint or footshock, or in association with 
expression of conditioned fear behavior [106-110]. Similarly, dopamine (DA) and 
norepinephrine (NE) levels in the amygdala are increased following restraint, handling 
stress, footshock or during the expression of conditioned fear behavior [107,111-118]. The 
source of monoamines to the amygdala arise from monoaminergic cell body regions in the 
brainstem. Specifically, the dorsal raphe nucleus (dRN) provides 5-HT innervation to the 
amygdala, while NE and DA innervation of the amygdala arise from the locus coeruleus 
(LC) and ventral tegmental area (VTA) respectively [55,119,120]. Regulation of 
monoaminergic activity in the amygdala thus can occur at the level of these brainstem cell 
body regions, or within the terminal regions of the amygdala. 
One of the important mediators of amygdala monoaminergic activity in response to 
anxiogenic or fearful stimuli is CRF. A strong body of evidence implicates central CRF in 
mediating fear and anxiety [12,121-128], and recent clinical studies suggest an important 
role for CRF in anxiety disorders [129]. Like anxiogenic and fearful stimuli, central infusion 
of CRF or CRF receptor agonists increases 5-HT, NE and DA levels in the amygdala [130-
133], and stress-induced increases in monoamine levels in the amygdala are prevented by 
CRF receptor antagonists [108,111]. It is thought that CRF regulation of monoaminergic 
activity in the amygdala occurs at the level of the monoaminergic cell bodies. The 
monoaminergic cell body regions receive CRF innervation from the CeA and BNST, and 
CRF type 1 and 2 (CRF1 and CRF2) receptors are localized to the dRN, LC and VTA [134-
140]. Direct infusion of CRF or CRF receptor agonists into the dRN stimulates 5-HT release 
in the CeA or BLA [131-133]. Interestingly, CRF-induced 5-HT release in the amygdala 
appears to be dependent on CRF2 receptor activation in the dRN [131,133], and CRF2 
receptors are known to increase 5-HT neuronal firing rates in the dRN [141]. Importantly, 
increased neuronal surface expression of CRF2 receptors occurs in the dRN as a result of 
stress [142], and increased expression of CRF2 receptors in the dRN has been observed in rat 
models of high anxiety [11,128,137,143]. Furthermore, CRF2 receptor antagonists infused 
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directly into the dRN reduce heightened anxiety-like behavior in rat models of 
amphetamine withdrawal or early life stress [12,128]. Combined, these findings suggest that 
CRF2 receptor modulation of 5-HT activity in the amygdala may play an important role in 
heightened anxiety. While similar studies have not been performed to elucidate the role of 
CRF receptors in the LC and VTA in mediating NE and DA activity in the amygdala and 
anxiety states, some indirect evidence suggests an important role for CRF receptors in the 
LC and VTA stress responses [136,138,144]. Overall, it is clear that further investigations are 
needed to ascertain the role of CRF receptors in mediating NE and DA activity in the 
amygdala and how CRF modulation of this activity could relate to fear or anxiety. 
Studies demonstrating increased monoamine activity in the amygdala in response to 
anxiogenic or fearful stimuli, and CRF modulation of these responses (as described above) 
do not allow conclusions to be made about the specific role of each monoamine in mediating 
anxiety or fear. Direct manipulation of monoaminergic activity within the amygdala or 
specific amygdala subregions, and the measurement of resultant anxiety-like or fear-related 
behaviors, have gone some way to providing a picture of how monoamine function in the 
amygdala might translate to anxiety or fear. Table 2 summarizes such studies directly 
manipulating 5-HT levels or 5-HT receptor activity in the amygdala. When 5-HT or 5-HT 
activity is decreased in the entire amygdala [145,146], a consistent increase in anxiety-like 
behavior is observed (Table 2). This would suggest that increased 5-HT activity in the 
amygdala would thus be associated with decreased anxiety, implying an anxiolytic role of 5-
HT. However, this does not appear to be supported by experiments that directly manipulate 
5-HT receptor activity in the amygdala with 5-HT receptor ligands (Table 2). For example, 
activation of postsynaptic excitatory 5-HT2 or 5-HT3 receptors in the amygdala decreases 
social interaction and increases anxiety-like behavior, whereas antagonism of 5-HT3 
receptors in particular increases social interaction and decreases anxiety-like behaviors, 
suggesting that 5-HT actions on postsynaptic receptors is anxiogenic (Table 2), although, see 
[147] for an exception to this pattern. Similarly, activation of excitatory 5HT2 receptors in the 
BLA generally increases anxiety-like behavior (Table 2), suggesting an anxiogenic role for 
postsynaptic 5-HT receptors in the BLA (although an exception to this is observed, [148]). In 
contrast, inhibitors of 5-HT2 receptors in the MeA increase anxiety-like behavior while 
activation of these receptors increases social interaction and decreases anxiety behavior 
(Table 2). Thus like the some findings from the amygdala as a whole (Table 2), 5-HT activity 
in the MeA appears to play an anxiolytic role. The role of 5-HT or 5-HT receptors has not 
been well studied in the CeA. However, rats undergoing amphetamine withdrawal that 
exhibit greater anxiety-like behavior have greater 5-HT release in the CeA [12,133], 
suggesting a similar anxiogenic relationship between 5-HT and anxiety as for the BLA. 
Future work should determine whether 5-HT in the CeA reduces anxiety-like behaviors as is 
suggestive for the MeA, or in contrast, increases anxiety-like behaviors as appears to be the 
case for the BLA. Overall, the findings summarized in Table 2 suggest a dichotomy in the 
potential role of 5-HT in the amygdala in mediating anxiety depending on whether the 
entire amygdala or a specific subregion is targeted. Potential confounds in comparing the 
studies listed in Table 2 could be the different paradigms used to measure anxiety-like 
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behaviors and the relative selectivity of 5-HT receptor ligands across different experiments. 
Future studies directly comparing the effects of 5-HT manipulations within the different 
amygdala subregions across several well-validated tests of anxiety-like behaviors will better 
elucidate the role of amygdala 5-HT in mediating anxiety. 
 
 
Amygdala Subregion
Monoamine or 
Receptor Involvement
 
Behavioral Outcome Citation
Anxiety-like Behavior
Amygdala Decreased 5-HT 
(induced by MDMA) 
Increased anxiety 
behavior  
Faria et al. [145] 
Amygdala Decreased 5-HIAA 
(induced by stress)
Increased anxiety 
behavior
Niwa et al. [146] 
Amygdala 5-HT1A agonist No change in anxiety 
behavior
Zangrossi and Graeff 
[149]
Amygdala 5-HT2B/2C agonist Increased anxiety 
behavior
Cornelio and Nunes-
De-Souza [150] 
Amygdala 5-HT3 agonist Decreased social 
interaction
Higgans et al. [151] 
Amygdala 5-HT3 agonist Decreased anxiety 
behavior
Costall et al. [147] 
Amygdala 5-HT3 antagonist Increased social 
interaction
Higgans et al. [151] 
Amygdala 5-HT3 antagonist Decreased anxiety 
behavior
Costall et al. [147] 
Amygdala 5-HT3 antagonist Decreased anxiety 
behavior
Tomkins et al. [152] 
BLA 5-HT1A agonist Decreased social 
interaction
Gonzalez et al. [153] 
BLA 5-HT1A agonist No change in anxiety 
behavior 
Gonzalez et al. [153] 
BLA 5-HT2A agonist Increased anxiety 
behavior
Zangrossi and Graeff 
[149]
BLA 5-HT2A/2C agonist No change in anxiety 
behavior
Cruz et al [148] 
BLA 5-HT2C agonist Increased anxiety 
behavior 
Vincente et al. [154] 
MeA 5-HT2A antagonist Increased anxiety 
behavior
Zangrossi and Graeff 
[149]
MeA 5-HT2 agonist No change in anxiety 
behavior
Duxon et al. [155] 
MeA 5-HT2B agonist Increased social 
interaction
Duxon et al. [156] 
MeA 5-HT2B agonist Decreased anxiety 
behavior
Duxon et al. [155] 
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Amygdala Subregion
Monoamine or 
Receptor Involvement
 
Behavioral Outcome Citation
MeA 5-HT2B/2C agonist No change in anxiety 
behavior 
Duxon et al. [155] 
Fear-related Behavior
CeA Increased 5-HT Increased 
unconditioned 
freezing
Forster et al. [132] 
BLA Increased 5-HT Decreased 
conditioned freezing 
Inoue et al. [157] 
BLA Increased 5-HT Decreased 
unconditioned tonic 
immobility
Leite-Panissi et al. 
[158] 
BLA 5-HT1A agonist Decreased 
conditioned freezing
Li et al. [159] 
BLA 5-HT1A agonist Decreased acquisition 
and expression of 
conditioned defeat
Morrison et al. [160] 
BLA 5-HT1A/2 agonist Decreased 
unconditioned tonic 
immobility
Leite-Panissi et al. 
[158] 
Abbreviations:  5-HIAA = 5-Hydroxyindoleacetic acid (5-HT metabolite); 5-HT = serotonin; BLA = basolateral 
amygdala; CeA = central nucleus of the amygdala; MDMA = 3,4-methylenedioxy-N-methylamphetamine; MeA = 
medial amygdala. 
Table 2. The Role of Serotonin in Anxiety-Like and Fear-Related Behaviors 
Determining the role of amygdala 5-HT in fear-related behavior has mainly utilized studies 
of freezing or immobility responses in rodents, and of 5-HT manipulation in the BLA (Table 
2). From these studies, it seems clear that 5-HT in the BLA decreases the expression of 
unconditioned and conditioned fear responses, likely via activation of the inhibitory 
postsynaptic 5-HT1A receptor (Table 2). Thus, it has been suggested that 5-HT in the 
BLA/amygdala ameliorates fear [8]. This conclusion is in contrast to the apparent role for 
BLA 5-HT in enhancing anxiety (Table 2), suggesting a fear versus anxiety dissociation for 
the role of 5-HT in the BLA. This dissociation, if upheld by more in-depth future work, 
could prove important information for the development of treatment strategies for the 
various anxiety disorders that differ in the degree of anxiety-like and fear-like 
symptomology (as discussed in Section 1.1).   
A role for amygdala DA in anxiety has not been as well explored as for 5-HT. However, a 
summary of studies that have manipulated DA function in the amygdala provides a 
consistent picture of the role of amygdala DA in mediating anxiety in animal models (Table 
3). Indirect evidence suggests that decreased DA in the amygdala leads to increased anxiety, 
and this is supported by direct manipulation of the CeA (Table 3). For example, decreased 
DA or DA receptor antagonism within the CeA 
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suggesting that DA activity in the CeA is anxiolytic. This role for DA in the CeA is in direct 
contrast to the BLA, where converging evidence suggests that decreased DA function in the 
BLA decreases anxiety-like behaviors while increased DA receptor activity in the BLA 
increases anxiety (Table 3). Thus, DA activity in the BLA is anxiogenic, revealing an 
opposite role for DA activity in the CeA and BLA in mediating anxiety-like behaviors in 
animal models.  
 
 
Amygdala Subregion
Monoamine or 
Receptor Involvement
 
Behavioral Outcome 
 
Citation 
Anxiety-like Behavior 
Amygdala Decreased DA Decreased rearing in 
open field indicative 
of increased anxiety 
behavior 
Summavielle et al. 
[163] 
CeA Decreased DA Decreased voluntary 
activity  indicative of 
increased anxiety 
behavior 
Izumo et al. [164] 
 
CeA D1 antagonist Increased anxiety 
behavior 
Rezayof et al. [165] 
CeA D2/3 antagonist Increased anxiety 
behavior  
de la Mora et al. [166] 
BLA DA depletion Decreased anxiety in 
males but not females
Sullivan et al. [167] 
BLA D1 agonist Increased anxiety 
behavior 
Banaej et al. [168] 
BLA D2 agonist Increased anxiety 
behavior 
Banaej et al. [168] 
BLA D1 antagonist Decreased anxiety 
behavior 
Banaej et al. [168] 
BLA D1 antagonist Decreased anxiety 
behavior 
de la Mora et al. [169] 
BLA D2 antagonist Decreased anxiety 
behavior 
Banaej et al. [168] 
Fear-related Behavior 
Amygdala D2 antagonist Decreased acquisition 
and retention of fear 
conditioning 
Greba et al. [170] 
 
 
CeA D1 agonist Increased conditioned 
fear behavior 
Guarraci et al. [171] 
CeA D1 antagonist Inhibited conditioned 
fear behavior 
Guarraci et al. [171] 
CeA D2 antagonist Decreased Guarraci et al. [172] 
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Amygdala Subregion
Monoamine or 
Receptor Involvement
 
Behavioral Outcome 
 
Citation 
conditioned fear 
behavior 
BLA DA depletion Decreased fear 
conditioning 
Seldon et al. [173] 
BLA D1 antagonist Inhibited acquisition 
of fear conditioning 
Greba and Kokkinidis 
[174] 
BLA D2 antagonist Inhibited fear 
potentiated startle 
De Oliveira et al. [175] 
Abbreviations:  BLA = basolateral amygdala; CeA = central nucleus of the amygdala; DA = dopamine. 
Table 3. The Role of Dopamine in Anxiety-Like and Fear-Related Behaviors 
In contrast, the role of DA in mediating fear-related behaviors does not appear to differ 
based on amygdala subregion (Table 3). Reducing DA function in the amygdala reduces or 
inhibits processes associated with fear conditioning, while increasing DA receptor activity 
increases conditioned fear (Table 3). Thus, DA in the amygdala is required for fear 
conditioning, and enhanced DA levels in the amygdala as elicited by fearful stimuli and 
conditioned cues [107,112] would thus facilitate fear conditioning. It should be noted that 
the studies summarized by Table 3 indicate a role for both excitatory D1 receptors and 
inhibitory D2 receptors. Dopamine D2 receptors are localized both pre- and post-
synaptically, with pre-synaptic D2 autoreceptors limiting DA neuronal activity and DA 
release [161,162]. Thus, antagonism of presynaptic D2 receptors would actually increase DA 
within the amygdala. Since the effects of D2 receptor antagonism on fear-related behaviors is 
characteristic of reduced, not enhanced, DA function in the amygdala, it may be concluded 
that the results of D2 receptor antagonism summarized by Table 3 are due to postsynaptic D2 
receptor effects. However, this conclusion requires direct testing. 
Very few studies have examined the role of amygdala NE in mediating anxiety-like 
behavior in animal models, surprising given that anxiogenic stimuli increase NE in this 
region [for example, see 111,115,116] and drugs that alter NE neurotransmission are used to 
treat anxiety disorders [8]. There appears to be little role for NE receptors in the CeA in 
mediating anxiety-like behavior, although infusion of a α1 antagonist can increase social 
interaction following an anxiogenic stimulus [restraint; 176; Table 4]. It is clear that more 
experiments are required to delineate the role of amygdala NE in mediating anxiety. 
Studies determining the role of NE in fear-related behaviors have concentrated on the BLA, 
due to the importance of this amygdala subregion in conditioned fear responses (see Section 
3.1.). The major focus of the studies summarized by Table 4 has been on the role of NE in 
fear conditioning and reconsolidation of fear memories in conditioned fear paradigms. 
Taken as a whole, findings suggest that NE in the BLA facilitates fear conditioning and fear 
memory, via activation of adrenergic β receptors (Table 4). Recent evidence suggests a role 
for α1 receptors in the BLA in mediating fear memory, in this case, activation of α1 receptors 
by NE would appear to decrease fear memory (Table 4). Thus, it is possible that NE in the 
 
The Role of the Amygdala in Anxiety Disorders 75 
BLA could have opposing effects on reconsolidation of fear memory based on the balance of 
α1 versus β receptor activity – a hypothesis that requires direct testing. The role of NE in the 
BLA (and β receptors in particular) in fear memory has generated interest in targeting this 
NE system for the treatment of anxiety disorders where enhancement in fear memory is 
apparent, such as PTSD [for example, see 177]. Whether NE within the BLA plays a role in 
other aspects of fear processing (e.g. unconditioned fear responses to non-olfactory based 
stimuli) or NE within other amygdala subregions mediate fear should be subjects of future 
investigations to fully elucidate the role of amygdala NE in fear. 
 
 
Amygdala Subregion
Monoamine or 
Receptor Involvement
 
Behavioral Outcome 
 
Citation 
Anxiety-like Behavior 
CeA α1 antagonist Increased social 
interaction 
Cecchi et al. [176] 
CeA α1 antagonist No effect on anxiety 
behavior 
Cecchi et al. [176] 
CeA β1/2 antagonist No effect on social 
interaction 
Cecchi et al. [176] 
CeA β1/2 antagonist No effect on anxiety 
behavior 
Cecchi et al. [176] 
Fear-related Behavior 
BLA Increased NE Increased memory 
and retention of fear 
conditioning 
LaLumiere et al. [178] 
BLA Decreased NE Impaired fear 
conditioning 
Seldon et al. [173] 
BLA Decreased NE Impaired fear 
memory 
Debiec and LeDoux 
[177] 
BLA α1 antagonist Increased fear 
memory 
 
Lazzaro et al. [179] 
BLA β1/2 antagonist Impaired of fear 
memory 
 
Debiec and LeDoux 
[180] 
BLA β1 antagonist Impaired fear 
memory (as enhanced 
by glucocorticoids) 
Roozendaal et al. 
[181] 
Abbreviations:  BLA = basolateral amygdala; CeA = central nucleus of the amygdala; NE = norepinephrine. 
Table 4. The Role of Norepinephrine in Anxiety-Like and Fear-Related Behaviors 
In summary, it is clear that more work is required to fully understand the role of amygdala 
monoamines in mediating fear and anxiety. However, several patterns of interest emerge 
from the current literature, namely that there are distinct subregion differences in the role 
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each monoamine plays in mediating anxiety and fear, with the one monoamine possibly 
playing opposing roles depending on subregion or depending on whether anxiety or fear 
measures are employed. Therefore, these findings suggest neurochemical dissociations 
between amygdala subregions and monoamines in mediating fear or anxiety. 
4. The amygdala as a potential site of anxiolytic drug action 
Psychopharmacological management of anxiety disorders includes the benzodiazepines, 
antidepressants, 5-HT1A agonists and various “off-label” drugs such as β-blockers, mood 
stabilizers and antipsychotics. The mechanism by which these drugs produce anti-anxiety 
effects has yet to be definitively established and represents a frequently updated field of 
research. Because these drugs bind to target receptors throughout the brain, it is unlikely 
that their efficacy can be attributed to action in one particular region. However, given the 
role that the amygdala plays in fear and anxiety, modification of amygdala function by 
pharmacological agents represents a likely mechanism of action as well as a target to guide 
future drug development. The evidence for amygdala involvement in anxiolytic action 
comes from both human imaging studies as well as work in animal models.   
4.1.  Human imaging studies: Effects of anxiolytics on amygdala activity and 
emotion 
Given the highly complex and subjective nature of anxiolytic drug response in humans, 
neuroimaging represents an invaluable tool for drug evaluation and discovery. 
Benzodiazepines: Benzodiazepines exert their anxiolytic action through binding to GABAA 
receptors, which leads to enhanced GABA activity and a subsequent increase in inhibitory 
tone. Despite the long history and current prevalence of benzodiazepine use for anxiety 
disorders [182,183], there is a paucity of human neuroimaging studies utilizing this class of 
drug, especially compared to those using antidepressants. This may have to do with eclipse 
of benzodiazepines by antidepressants as first line agents for many anxiety disorders [182].  
Various studies have utilized healthy volunteers undergoing experimental challenges in an 
attempt to elucidate the neurobiology underlying the anxiolytic effect of benzodiazepines. 
These studies have found that benzodiazepines have the ability to impair functions related 
to amygdala activity including fear conditioning [184-186], recognition of fearful emotional 
faces [187], and memory for emotional stimuli relative to neutral stimuli [188,189]. 
Neuroimaging work appears to support a role for the amygdala in benzodiazepine action, 
although this may be dependent upon the nature of the accompanying neuropsychological 
challenge. Specifically, lorazepam was found to decrease amygdala activation during an 
emotional face assessment task without modifying baseline levels of anxiety or task 
recognition [190]. A similar finding was found with diazepam, which decreased amygdala 
response to fearful faces, and also impaired fearful face recognition [191]. However, during 
anticipation of aversive electrical stimulation, lorazepam failed to produce changes in 
amygdala activity [192]. Thus, while there is support for benzodiazepine induced 
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modulation of the amygdala during processing of threatening/emotional stimuli, further 
studies are needed to clarify the neural correlates of benzodiazepine-induced anxiolysis.   
β-Blockers: The β-blocker propranolol has a substantial history of being utilized to reduce 
somatic symptoms of fear and anxiety in situations such as stage fright [193] and acute panic 
[194-195]. More recently, research on the role of amygdala NE and β-receptors in facilitating 
emotional memory formation (see Table 4 and associated text) has caused much excitement 
and controversy about the use of propranolol to prevent PTSD [196-198]. Thus far, initial 
trials have demonstrated limited efficacy [199,200]. Despite lack of success in the application 
of propranolol to PTSD, neuroimaging studies in healthy human subjects have confirmed 
the ability of propranolol to modulate amygdala activation to emotional stimuli. 
Propranolol was found to decrease amygdala activation to emotional faces irrespective of 
emotional valence [201]. Furthermore, supporting a role for the amygdala NE in the 
encoding and consolidation of emotional stimuli, a separate study found that propranolol 
was able to decrease amygdala reactivity to emotional pictures of high valence as well as 
decrease the subject’s memory for them [202].  
Selective Serotonin Re-uptake Inhibitors: Antidepressant drugs, and selective serotonin re-
uptake inhibitors (SSRIs) in particular, have become first line drugs for many of the anxiety 
disorders [182,203]. As such, there has been comparatively more work investigating these 
drugs in humans using advanced imaging techniques.   
Most antidepressants are unique from benzodiazepines and β-blockers in that a time lag 
exists between initial treatment and onset of anxiolytic effects. In line with a potential 
anxiogenic role of serotonin in the amygdala (see Table 2 and associated text), some patients 
have reported an initial exacerbation of anxiety upon acute dosing of SSRIs [203]. In studies 
on healthy subjects, acute dosing of the SSRI citalopram can enhance recognition of fearful 
faces as well as increase emotion-potentiated startle response [204-206]. These effects are 
reversed when citalopram treatment is continued for 7 days [207,208].  
Attempts to correlate the acute versus sub-chronic effects of SSRIs with neural activation 
have resulted in unexpected findings. On one hand, sub-chronic citalopram treatment was 
found to decrease amygdala activation to unconscious fearful stimuli [209], suggesting a 
relationship between repeated SSRI treatment, changes in emotional processing, and 
decreased amygdala activity. However, acute doses of citalopram have also been found to 
decrease amygdala activation to fearful faces [208,210,211]. Divergent effects of acute versus 
sub-chronic citalopram on emotional recognition but similar effects on amygdala response 
could suggest that the amygdala does not play a core role in acute SSRI-induced anxiety or 
chronic SSRI-induced anxiolysis. However, it has been emphasized that the effects of 
serotonergic challenge on fear recognition and amygdala activation appear to be dependent 
upon the individual’s baseline sensitivity to threat [212], gender [213] and genotype [214]. 
Thus differences in subject profiles both between and within studies could have confounded 
results.   
Overall, it appears that pharmacotheraputics commonly used to treat anxiety disorders may 
modulate amygdala function. In particular, it appears that anxiolytics can reduce amygdala 
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reactivity to highly emotive or fearful stimuli. Given that amygdala hyper-reactivity to 
similar stimuli is the most common finding across all anxiety disorders (with the exception 
of adult GAD – see Section 2.2), it is possible that the anxiolytic effects of these drugs may be 
in part, mediated by dampening amygdala function. 
4.2. Evidence delineating effects of anxiolytic drugs on amygdala function in 
animal models of anxiety states 
Benzodiazepines: While benzodiazepine receptors exist throughout the brain, there is a 
particularly high density in amygdala regions [215,216]. There is much evidence from 
animal models to suggest that it is the action of benzodiazepines in the amygdala that 
mediates their anxiolytic effect. For example, early evidence demonstrated that local 
amygdala infusion of benzodiazepines produces anxiolytic-like effects in conflict models of 
anxiety [217-220]. These effects can be reversed by systemic [217,219]  or direct amygdala 
administration of benzodiazepine antagonists [220]. Anti-conflict effects are most apparent 
when the benzodiazepines are injected into the BLA, and are absent when injected into the 
CeA [219,220]. While anti-conflict effects of benzodiazepines have been observed in the CeA, 
these were with substantially higher doses [221]. Further studies suggest that the BLA and 
not the CeA is essential for the anxiolytic effects of benzodiazepines in the EPM 
[149,222,223]. However, with regards to the shock probe burying test, it appears that the 
CeA is responsible for benzodiazepine-induced impairment of passive avoidance [223]. 
Although contradictory results exist on the role of benzodiazepines in the BLA versus CeA, 
particularly when animals are tested on the EPM [9,84,224] have suggested that distinct 
benzodiazepine receptor subtypes located within subregions of the amygdala may 
differentially alter avoidance responses to “potential threat” (EPM and BLA) versus 
“discrete, unambiguous threat” (shock probe burying and CeA).   
As discussed in the human studies in Section 4.1 above [184,188,189], a key aspect of 
benzodiazepine action may be the ability to modulate emotional memory. Here the BLA 
once again appears to be a main site of benzodiazepine action. Lesions of the BLA, but not 
the CeA, block the benzodiazepine induced deficits in inhibitory avoidance memory 
[225,226]. Similar impairments were seen by direct injection of benzodiazepine into the BLA 
and not the CeA [227]. Enhancement of memory consolidation could be induced by BLA 
infusion of a benzodiazepine antagonist [228]. Given that individuals with anxiety disorders 
may be hypervigilant to cues associated with threatening stimuli and biased to form 
memories regarding such stimuli [229,230],  the pro-amnestic effects of benzodiazepines in 
the BLA may represent a putative mechanism of action.  
β-Blockers: The evaluation of β-blockers (with propranolol being the prototypical agent) in 
animal models has revolved mainly around their utility in models of memory and fear 
conditioning. Within the BLA, stress hormone elicited increases in norepinephrine have 
been found to enhance the consolidation of emotionally relevant memories [231,232]. This 
appears to be particularly true with contextual fear conditioning [178] and reconsolidation 
of fear memory following extinction [180,197,233; Table 4]. In particular, local infusions of 
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propranolol are able to block reconsolidation of fear [180,233]. Recently, it has been 
demonstrated that β-adrenoreceptor activation within the BLA decreases surface expression 
of GABAA receptors, and this phenomenon is necessary for the reinstatement of fear 
following extinction [234]. It is proposed that propranolol, through blocking the decrease in 
GABAA receptor surface expression, prevents fear reinstatement by maintaining feed 
forward inhibition from BLA interneurons and thus dampening activity of BLA projections 
[234]. This finding is noteworthy as it suggests that hyperactive noradrenergic activity in 
PTSD [235,236] may lead to reduced GABAA availability, explaining a potential mechanism 
for the relative ineffectiveness of benzodiazepines in PTSD populations [237,238].  
Despite the action of β-blockers within the amygdala to modulate fear conditioning (see 
Table 4), attempts at testing propranolol in other animal models of PTSD have met with 
mixed results, echoing the mixed efficacy seen thus far in humans [199,200,239,240]. One 
such model is exposure to predator odor in rodents, which produces long lasting increases 
in anxiety like behavior [241-243]. The increases in anxiety like behavior following exposure 
to predator odor is influenced by a long lasting potentiation in BLA activity [243], 
supporting the role of the amygdala in mediating the consequences of fear and trauma. 
Propranolol administered 1 minute following exposure to predator odor to rats blocks the 
development of anxiogenesis in various tests, including the EPM, one week later [241]. 
However, when propranolol administration is delayed to 1 hour following predator odor 
exposure, no effects are seen when rats are subsequently tested on the EPM 30 days later 
[242]. These results highlight once again a potential key role of timing if propranolol is to be 
effectively implemented in clinical patients. Similarly, findings that propranolol seems most 
effective in blocking the reconsolidation of fearful memories [233, 180, 197] (also see Table 4) 
suggests that future work should be aimed at establishing protocols for the integration of 
propranolol during exposure therapy, in which extinction and reconsolidation processes are 
most active. Specifically, it would seem important that propranolol not be administered 
shortly after exposure therapy, as this might interfere reconsolidation processes within the 
amygdala.  On the other hand, propranolol would likely have utility when PTSD patients 
encounter aversive stimuli outside the context of therapy which could potentially 
undermine the therapeutic process and lead to reinstatement. 
Selective Serotonin Re-uptake Inhibitors: Similar to human studies, animal models of anxiety-
like behavior demonstrate divergent behavioral effects of acute versus chronic SSRI 
administration. Increased anxiety-like behavior with acute treatment of SSRIs and its 
reversal with chronic treatment has been found in novelty-suppressed feeding [244], EPM 
testing [245,246], and the social interaction test [247]. While a large percentage of studies 
reveal acute anxiogenic effects and chronic anxiolytic effect, there are exceptions (for review, 
see [248]).  
Much evidence suggests that enhanced activity at 5-HT2C within the BLA by SSRIs produces 
acute anxiogenic effects, while the eventual downregulation of these receptors by chronic 
treatment leads to eventual anxiolysis. For example, amygdala or BLA 5-HT2C receptors 
have been found to produce anxiety-like responses in a variety of tests [249,250] (see Table 
2). Blockade of 5-HT2C receptors within the BLA prevents the acute anxiogenic effect of the 
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SSRI fluoxetine on the Vogel conflict test [251]. Systemic 5-HT2C antagonism also prevents 
the increase in fear conditioning [252], decrease in social interaction [247,253], and escape 
response to airjet [254] following acute SSRI treatment. Following chronic treatment with 
SSRIs, 5-HT2C agonists have attenuated anxiogenic effects on the exacerbation of OCD 
symptoms in humans [255,256], on social interaction [257] and hyperlocomotion [258], 
suggesting down-regulation of the ability to 5-HT2C receptors in the amygdala to produce 
anxiogenic responses following chronic SSRI treatment. Thus, the amygdala (BLA in 
particular) may be an important locus of action for the long-term effects of SSRIs on anxiety. 
4.3. Future potential anxiolytic targets 
The literature reviewed above suggests that in part, the effects of anxiolytic drugs may be 
mediated by altering amygdala function – either global dampening of the amygdala by 
benzodiazepines, or specific actions on 5-HT and NE receptors within particular amygdala 
subregions. However, to improve therapeutic efficacy and reduce relapse, several aspects of 
amygdala pharmacology discussed above might provide useful potential anxiolytic targets 
in the future. 
Findings suggesting down-regulation of anxiogenic 5-HT2C receptors in the amygdala 
following chronic SSRI treatment (Section 4.2.) present a potential strategy of reducing onset 
latency of SSRIs as well as enhancing their effects. Specifically, blocking 5-HT2C receptors at 
the initiation of SSRI treatment would be expected to produce a faster onset of anxiolytic 
action. Currently, there are no selective 5-HT2C antagonists available for human use. 
However, atypical antipsychotics [259] as well as atypical antidepressants such as 
mirtazapine [260] possess 5-HT2C antagonist activity. While there is evidence that 
antipsychotic augmentation of SSRIs may improve anxiolytic efficacy, their use has been 
limited by poor tolerability [for review see 261]. Although research is lacking, mirtazapine 
and the melatonin receptor agonist/5-HT2C receptor antagonist agomelatine [262] may 
provide the advantage of targeting anxiogenic 5-HT2C in the amygdala with less side effects. 
Furthermore, the recent observation that β-adrenoreceptor activation within the BLA results 
in decreased of GABAA receptor surface expression necessary for fear reinstatement [234] 
(and see Section 4.2.) suggests that the combination of propranolol and a benzodiazepine 
may have unique benefit for PTSD. By blocking β-adrenoreceptors with propranolol, one 
might be able to enhance benzodiazepine receptor availability, and increase 
benzodiazepine-induced inhibition of fear circuits within the amygdala. While currently 
speculative, the use of propranolol to enhance benzodiazepine action in the amygdala may 
represent a potential creative treatment strategy in a population that is traditionally 
refractory to benzodiazepine treatment.   
While current pharmacotherapeutic strategies for the treatment of anxiety disorders target 
monoamine function, this has predominantly been related to altering 5-HT or NE levels or 
receptor activity [8]. However, Table 3 clearly shows a role for DA in the amygdala in 
mediating both fear and anxiety, and the role for DA and both D1 and D2 receptors in 
acquisition and retention of conditioned fear in particular appears quite robust. Thus, 
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reducing DA function might serve as means by which to treat anxiety disorders in which 
fear plays a major component. The obvious disadvantage of dopaminergic-based 
pharmacotheraputics is potential for major cognitive and motoric side-effects, limiting the 
treatment options with the currently available dopaminergic agents. Atypical antipsychotic 
drugs incorporate DA receptor blocking activity while avoiding many of the motoric and 
cognitive issues of traditional agents. There is evidence that atypical agents possess 
anxiolytic activity [261], but metabolic side effects make them poorly tolerated. Furthermore, 
because atypical antipsychotics also have high affinity for 5-HT receptors, the contribution 
of DA modulation to their anxiolytic effects in humans is currently unknown. One potential 
strategy may be the use of partial agonists to reduce DA activity in the amygdala via 
activation of inhibitory presynaptic D2 autoreceptors. While non-selective for DA, the D2 
partial agonist aripiprazole has demonstrated anxiolytic efficacy similar to other atypical 
antipsychotic drugs [263]. In the future, more selective DA partial agonists may have 
additional benefit without unwanted side-effects.  
Finally, CRF has been identified as an important neuropeptide in the regulation of 
monoaminergic activity in the amygdala in response to anxiogenic or fearful stimuli (Section 
3.2). Furthermore, CRF and its receptors (CRF1 and CRF2) are implicated in fear and anxiety 
within animal models and in the development of anxiety disorders [12,121-129]. Upon the 
development of non-peptide CRF1 receptor antagonists that cross the blood-brain barrier, 
there was great interest in the use of CRF1 receptor antagonist in the treatment of anxiety 
disorders. To date, there have been limited phase II clinical trials published regarding the 
use of CRF1 receptor antagonists in anxiety disorders [264]. Of those, preliminary findings 
suggest the CRF1 receptor antagonist-treated groups did not differ from placebo-treated 
groups in anxiety symptomology in both social anxiety disorder and GAD [264]. However, 
it has been suggested that efficacious concentrations have not been established for the 
various CRF1 receptor antagonists, and it is clear that further clinical trials are necessary. 
One potential promising area in the treatment of anxiety disorders may actually lie in CRF2 
receptor antagonists. As outlined in Section 3.2, CRF2 receptors mediate 5-HT activity in the 
amygdala, are up-regulated in animal models of anxiety, and an antagonist of this receptor 
reduces heightened anxiety in rats [11,12,127,128,131,132,137). The challenge lies in 
developing non-peptide CRF2 receptor antagonists that cross the blood-brain barrier, so that 
the efficacy of such ligands can be determined for anxiety disorders. 
5. Conclusion 
Human imaging studies in non-patient populations suggest amygdala activation in 
response to fearful stimuli, and that the magnitude of this response is positively correlated 
with trait anxiety. Furthermore, individuals suffering from an anxiety disorder (with the 
possible exception of adult GAD) show exaggerated amygdala responses to fearful or 
emotive stimuli, which again is positively correlated with the severity of symptoms. 
Moreover, reactivity of the amygdala to fearful stimuli is reduced by anxiolytic drugs in 
healthy subjects, and long-term pharmacotherapy or CBT reduces amygdala hyper-
reactivity in anxiety disorders. Animal studies corroborate an important role for the 
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amygdala in fear and anxiety, with specific subregions mediating acquisition and expression 
of fear, fear memories and anxiety, and the monoamines within each of these regions often 
playing a very specific role in facilitating or attenuating fear or anxiety. Both human and 
animal studies suggest dysfunction of the amygdala might arise in part, from inadequate 
top-down control by regions such as the medial prefrontal cortex, and in part, from altered 
neuropeptide regulation of amygdala monoaminergic systems. Overall, the amygdala plays 
a critical role in anxiety disorders, and understanding the function of this region in fear and 
anxiety states and how dysfunction of the amygdala results in anxiety disorders is critical to 
improving long-term treatment outcomes. 
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